Reach Solutions Reach Helpdesk Global regulatory compliance helpdesk Reach Solutions Reach Helpdesk

Veterinary Products

EU Directive 2001/82/EC relating to veterinary medicinal products

Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products will apply to all veterinary medicinal products, with the exception of:

  • Medicated feedingstuffs;
  • Inactivated immunological medicinal products which are manufactured from pathogens obtained from an animal from the same holding;
  • Medicinal products prepared in a pharmacy in accordance with a “magistral” or “official” formula;
  • Medicinal products based on radioactive isotopes;
  • Certain additives incorporated into animal feeding stuffs.

To take better account of the emergence of new therapies, such as cell therapies, the definition of veterinary medicinal product was amended in 2004. Further amendments were made in the year 2009.

Manufacture and import
The Member States must make subject to the holding of an authorisation:

  • Total or partial manufacture of the veterinary medicinal products and the various processes of dividing up, packaging or presentation (unless these processes are carried out by pharmacists for retail supply);
  • Importing of veterinary medicinal products.

Applicants for manufacturing or import authorisations must have suitable premises and equipment and at least one qualified person (as defined in the Directive).

Marketing authorization
No veterinary medicinal product (with the exception, under certain conditions, of those for aquarium fish, cage birds, homing pigeons, terrarium animals and small rodents) may be placed on the European Union (EU) market without a marketing authorisation. In exceptional cases, where required by the health situation or in the event of a serious disease epidemic, derogation from this principle may be permitted.

Medicinal products intended for food producing species may only be granted a marketing authorisation if the active substances they contain are listed in Regulation (EEC) No 2377/90 on residue limits of veterinary medicinal products in foodstuffs of animal origin.

No veterinary medicinal product may be administered to animals unless a marketing authorisation has been issued, except for the purpose of product testing.

The authorisation is issued by the competent authority of the Member State concerned or, where the centralised procedure established by Regulation (EEC) No 726/2004 applies, by the European Agency for the Evaluation of Medicinal Products (“the Agency”). A marketing authorisation may only be granted to an applicant established in the EU.

Documentation Required
Various particulars must be appended to the application for a marketing authorisation

  • composition and characteristics of the medicinal product,
  • manufacturing method,
  • therapeutic indications,
  • contra-indications and adverse reactions,
  • indication of the withdrawal period in order to limit the level of product residues in foodstuffs,
  • control methods,
  • results of toxicological and pharmacological tests and clinical trials,
  • copy of any marketing authorisation or refusal of marketing authorisation issued in another Member State, etc..

The documents and particulars supplied to the competent authorities must be drafted by experts with the requisite qualifications and analyses must be carried out in accordance with the guidelines in Annex 1.

Quotes from Companies

Your Nagpur Team has always provided polite professional,prompt and importantly competent advice and action. Instills confidence in the confidentialit...

Thanks for your valued & timely support.....

We are very much appreciating your so fast response and nice support for providing us these documents.....

Thank you Dr Datta. This makes life simple.
....

First of all I would like to congratulate you and your prestigious organisation on the grand success of REACH symposium held on 7th and 8th of April i....

We attended the Symposium on REACH on 8th April, 2011. Many things have got clarified there. Entire program was nice and successful.....

Thanks for the informative presentation on REACH (about the REACH Symposium held at Mumbai)....

Informative and useful Symposium on REACH Regulation.....

Thanks for your extended cooperation towards REACH Registration.....

The (IUCLID Training) session was very well prepared with good presentation and supporting documentation. Learning by ‘doing’ is put into applicat....

Many thanks for your email, giving the technical Updates on REACH Compliance and information on Letter of Access (LOA). We have found the information ....

Thank you for all the support given by you and your professional team through out the first introduction/awareness seminar of REACH till pre-registrat....

Our experience of working with REACH Support officials has been very cordial, informative and supportive. We look forward for a long association with ....

Thanks for providing valuable updates during the course of discussions in Mumbai....

Thank you for completing the registration of our substances well on time. We count on your support for registration of our substances in next slab as ....

I thank the complete REACH support team for the great work and cooperation. It has been a great learning experience for me and our company. I look for....